Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Nuvo Pharmaceuticals Inc > Market Cap - Too Low
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by daydream1on Aug 19, 2019 9:56am
142 Views
Post# 30042602

RE:RE:Market Cap - Too Low

RE:RE:Market Cap - Too LowAlso, you have to be mindful that the presently traded share price is not just a reflection of the present financial book value only. It is the future value of the company that is reflected. If you look at all the patents from the Aralez acquisition you will notice that are only valid for 4 up to about 7 years, not mentioning  the recent loss of Vimovo rights.

My opinion is the only investor that will benefit from NRI is Deerfield (and of course mmg via they options). Deerfield will get back their investment from the Aralez fiasco they were in and some more, even if they have to drain NRI value. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities